Sandbox : anmol

Hyperparathyroidism Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hyperparathyroidism from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Sandbox : anmol On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Sandbox : anmol All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Sandbox : anmol
CDC on Sandbox : anmol
Sandbox : anmol in the news
Blogs on Sandbox : anmol
Directions to Hospitals Treating Hyperparathyroidism
Risk calculators and risk factors for Sandbox : anmol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]

Pathogenesis

• GSD type 1 results due to defects in the function of microsomal enzyme glucose-6-phosphatase (G6Pase).
• G6Pase catalyzes the conversion of glucose-6-phosphate to glucose during glycogenolysis and gluconeogenesis.
• G6Pase is primarily expressed in expressed primarily in the gluconeogenic the liver and kidney. It is also expressed to a lesser extent in the intestine and pancreas.
• 80% Cases of GSD 1 are of GSD type 1a.